变应性鼻炎药物联邦审批过程中的群体人口学差异
该研究通过《信息自由法》获取美国食品药品监督管理局(FDA)自1990年以来批准用于变应性鼻炎(AR)的所有新药申请(NDA)和生物制品许可申请(BLA)的临床试验文档,提取人口学数据并与美国人口普查数据比较。结果显示,22种获批药物的临床试验中,种族、民族和性别构成均与AR患者群体及美国人口普查数据存在显著差异(p < 0.05),白种人占比过高,而黑人、亚裔、太平洋岛民、美洲原住民和西班牙裔占比不足。结论认为,支持FDA批准AR药物的临床试验人群不能代表美国人口或AR患者的人口学特征。
要点
- 自1990年以来获批的22种AR药物,其临床试验人群的种族、民族和性别构成与AR患者及美国人口普查数据均存在显著差异(p < 0.05)。
- 多数NDA和BLA中白种人受试者占比过高,黑人、亚裔、太平洋岛民、美洲原住民和西班牙裔受试者占比不足。
- 支持FDA批准AR药物的临床试验人群不能代表美国人口或AR患者的人口学特征。
核心结论
- 用于支持FDA批准AR药物的临床试验入组患者不能代表美国人口或AR患者的人口学特征。
- 研究人群与治疗人群之间人口学特征不具代表性的临床意义已在多种疾病中研究,但尚未在AR中研究。
研究设计与样本
- 通过美国《信息自由法》请求获取自1990年以来所有相关NDA和BLA的文档,并查询Drugs@FDA数据库获取所有临床试验文档。
- 从用于支持FDA批准AR药物的临床试验中提取人口学数据,并与美国人口普查数据进行比较分析。
- 证据等级为4级,发表于《喉镜》(Laryngoscope)2023年133卷755-763页。
主要发现
- 自1990年以来,共有22种药物获批用于AR。
- 所有纳入研究人群的种族、民族和性别构成与美国人口普查数据及AR患者人口学特征相比均存在显著差异(p < 0.05)。
- 多数NDA和BLA中白种人受试者占比过高,黑人、亚裔、太平洋岛民、美洲原住民和西班牙裔受试者占比不足。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Demographic minorities are underrepresented in clinical trials. For the approval of new drug applications (NDAs), the Food and Drug Administration (FDA) has asserted that clinical trial enrollment should represent the demographics of patients likely to receive the trial drug. The aim of this study is to assess the demographics of clinical trials included in NDAs and biologics license applications (BLAs) approved by the FDA since 1990 for allergic rhinitis (AR), a condition whose demographic prevalence mirrors the US population. METHODS: Federal Freedom of Information Act requests were submitted to the US government to obtain documents related to all relevant NDAs and BLAs. The Drugs@FDA database was queried for all clinical trial documentation. Demographic data were extracted from clinical trials used to inform FDA approval for AR pharmacotherapies. Demographics were analyzed relative to national US Census data. RESULTS: Since 1990, 22 drugs have been approved for AR. The racial, ethnic, and sex composition of all included study populations differed significantly (p < 0.05) from the demographics of AR and from US Census data. Most NDAs and BLAs included overrepresentation of White participants and underrepresentation of Black, Asian, Pacific Island, Native American, and Hispanic participants. CONCLUSION: The patients enrolled in clinical trials used to inform FDA approval for AR pharmacotherapeutics do not represent the demographics of the United States or the demographics of AR. The clinical significance of unrepresentative demography between study and treatment populations has been examined for several medical disorders, but has not been studied for AR. LEVEL OF EVIDENCE: 4 Laryngoscope, 133:755-763, 2023.
引用
- Liebowitz A, Spielman DB, Schlosser RJ, et al. Demographic Disparities in the Federal Drug Approval Process for Allergic Rhinitis Medications. Laryngoscope. 2022. PMID: 35394648. doi:10.1002/lary.30129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。